炎症与抗炎治疗对强直性脊柱炎患者主要心血管事件发生率的影响:一项基于人群的研究
该回顾性队列研究纳入2006至2015年间地区数据库中的3827例强直性脊柱炎患者,随访至2018年底,中位随访共23275人年,135例(3.5%)发生首次主要不良心血管事件(MACE)。多变量时变Cox模型显示,高炎症负荷(ESR、CRP升高)为MACE的独立预测因素,而柳氮磺吡啶(SLZ)使用与MACE风险降低相关。
要点
- ESR≥30 mm/h者MACE风险升高(HR 1.94),CRP>3 mg/dl者MACE风险升高(HR 5.43)。
- SLZ使用与MACE风险降低相关(HR 0.41-0.52)。
- 糖皮质激素、生物制剂及非COX-II抑制剂在单变量分析中与MACE相关,多变量调整后未保持显著。
核心结论
- 高炎症负荷是强直性脊柱炎患者发生MACE的独立预测因素,SLZ使用可能降低MACE风险。
研究设计与样本
- 回顾性队列研究,从地区数据库选取2006至2015年间强直性脊柱炎患者,随访至2018年底,共纳入3827例(平均年龄45.2±15.0岁,男性2911例[76.1%]),随访23275人年。
主要发现
- 随访期间135例(3.5%)发生首次MACE。
- 单变量分析中,ESR和CRP升高及糖皮质激素使用与MACE风险显著升高相关,SLZ、生物DMARDs及非COX-II抑制剂使用与MACE风险降低相关。
- 多变量调整传统心血管危险因素后,仅ESR(HR 1.02;ESR≥30 mm/h,HR 1.94)和CRP(HR 1.14;CRP>3 mg/dl,HR 5.43)仍与MACE风险升高显著相关,SLZ使用(HR 0.41-0.52)与MACE风险降低相关。
关键数值与推荐
- ESR每升高1单位,MACE风险HR 1.02;ESR≥30 mm/h者HR 1.94。
- CRP每升高1单位,MACE风险HR 1.14;CRP>3 mg/dl者HR 5.43。
- SLZ使用与MACE风险降低相关,HR 0.41-0.52。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the independent effect of inflammatory burden and various treatments on the risk of incident major adverse cardiovascular events (MACE) in ankylosing spondylitis (AS) patients. METHODS: AS patients were retrospectively selected from a territory-wide database between 2006 and 2015, and were followed until the end of 2018. The primary outcome was the first occurrence of MACE. Multivariate time-varying Cox proportional hazard models were used to determine the associations between inflammatory burden (measured by c-reactive protein [CRP] and erythrocyte sedimentation rate [ESR]) and different therapies with incident MACE, after adjusting for traditional cardiovascular (CV) risk factors. RESULTS: A total of 3827 patients with AS (mean age: 45.2 ± 15.0 years, male: 2911 [76.1 %]) were recruited. After a follow-up of 23,275 person-years, 135 patients (3.5 %) developed a first MACE. Univariate analyses showed that elevated ESR and CRP levels, and the use of glucocorticoids were associated with a significantly higher risk of MACE, while the use of sulfasalazine (SLZ), biologic DMARDs and non-cyclooxygenase-2 inhibitors (non-COX-IIi) were associated with reduced risk of MACE. After adjusting for CV risk factors in the multivariable models, only ESR (HR: 1.02; ESR ≥30 mm/h, HR:1.94) and CRP level (HR: 1.14; CRP >3 mg/dl HR:5.43) remained significantly associated with increased risk of MACE, while SLZ use (HR: 0.41-0.52) was protective against MACE. CONCLUSION: High inflammatory burden was an independent predictor associated with an increased risk of MACE, while the use of SLZ might reduce risk of incident MACE in patients with AS.
引用
- Shi LH, Lam SHM, So H, et al. Impact of inflammation and anti-inflammatory therapies on the incidence of major cardiovascular events in patients with ankylosing spondylitis: A population-based study. Semin Arthritis Rheum. 2024. PMID: 38852501. doi:10.1016/j.semarthrit.2024.152477
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。